Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | NSCLC | Research

Down-regulation of ERAP1 mRNA expression in non-small cell lung cancer

Authors: Marta Wagner, Maciej Sobczyński, Monika Jasek, Konrad Pawełczyk, Irena Porębska, Piotr Kuśnierczyk, Andrzej Wiśniewski

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

ERAP1 is a major aminopeptidase that serves as an editor of the peptide repertoire by trimming N-terminal residues of antigenic peptides, creating a pool of peptides with the optimal length for MHC-I binding. As an important component of the antigen processing and presenting machinery – APM, ERAP1 is frequently down-regulated in many cancers. Since ERAP1 expression has not yet been thoroughly investigated in non-small cell lung cancer (NSCLC), we decided to analyze ERAP1 mRNA levels in tissues collected from NSCLC patients.

Methods

Using real-time qPCR, we evaluated ERAP1 mRNA expression in samples of tumor and adjacent non-tumor tissue (serving as control tissue) from 61 NSCLC patients.

Results

We observed a significantly lower level of ERAP1 mRNA expression in tumor tissue (MedTumor = 0.75) in comparison to non-tumor tissue (MedNon-tumor = 1.1), p = 0.008. One of the five tested polymorphisms, namely rs26653, turned out to be significantly associated with ERAP1 expression in non-tumor tissue (difference [d] = 0.59 CI95% (0.14;1.05), p = 0.0086), but not in tumor tissue.
The levels of ERAP1 mRNA expression did not affect the overall survival of NSCLC patients, either in the case of the tumor (p = 0.788) or in non-tumor (p = 0.298) tissue.
We did not detect any association between mRNA ERAP1 expression level in normal tissue and: (i) age at diagnosis (p = 0.8386), (ii) patient’s sex (p = 0.3616), (iii) histological type of cancer (p = 0.7580) and (iv) clinical stage of NSCLC (p = 0.7549). Furthermore, in the case of tumor tissue none of the abovementioned clinical parameters were associated with ERAP1 expression (p = 0.76).

Conclusion

Down-regulation of ERAP1 mRNA observed in NSCLC tissue may be related to tumor immune evasion strategy. The rs26653 polymorphism can be considered an expression quantitative trait locus (eQTL) associated with ERAP1 expression in normal lung tissue.
Appendix
Available only for authorised users
Literature
1.
go back to reference D’Alicandro V, Romania P, Melaiu O, Fruci D. Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases. Mol Immunol. 2019;113:11–5.CrossRefPubMed D’Alicandro V, Romania P, Melaiu O, Fruci D. Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases. Mol Immunol. 2019;113:11–5.CrossRefPubMed
2.
go back to reference Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology. 2017;150(1):16–24.CrossRefPubMed Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology. 2017;150(1):16–24.CrossRefPubMed
3.
go back to reference Compagnone M, Cifaldi L, Fruci D. Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer. Hum Immunol. 2019;80(5):318–24.CrossRefPubMed Compagnone M, Cifaldi L, Fruci D. Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer. Hum Immunol. 2019;80(5):318–24.CrossRefPubMed
5.
go back to reference Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105(16):1172–87.CrossRefPubMed Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105(16):1172–87.CrossRefPubMed
6.
go back to reference Fruci D, Giacomini P, Nicotra MR, Forloni M, Fraioli R, Saveanu L, et al. Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol. 2008;216(3):742–9.CrossRefPubMed Fruci D, Giacomini P, Nicotra MR, Forloni M, Fraioli R, Saveanu L, et al. Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol. 2008;216(3):742–9.CrossRefPubMed
7.
go back to reference Ayshamgul H, Ma H, Ilyar S, Zhang LW, Abulizi A. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chin Med J (Engl). 2011;124(3):341–6.PubMed Ayshamgul H, Ma H, Ilyar S, Zhang LW, Abulizi A. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chin Med J (Engl). 2011;124(3):341–6.PubMed
8.
go back to reference Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. Oncoimmunology. 2017;6(5):e1305531.CrossRefPubMedPubMedCentral Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. Oncoimmunology. 2017;6(5):e1305531.CrossRefPubMedPubMedCentral
9.
go back to reference Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008;57(2):197–206.CrossRefPubMed Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008;57(2):197–206.CrossRefPubMed
10.
go back to reference Wiśniewski A, Sobczyński M, Pawełczyk K, Porębska I, Jasek M, Wagner M, et al. Polymorphisms of Antigen-Presenting Machinery Genes in Non-Small Cell Lung Cancer: Different Impact on Disease Risk and Clinical Parameters in Smokers and Never-Smokers. Front Immunol. 2021;12:664474.CrossRefPubMedPubMedCentral Wiśniewski A, Sobczyński M, Pawełczyk K, Porębska I, Jasek M, Wagner M, et al. Polymorphisms of Antigen-Presenting Machinery Genes in Non-Small Cell Lung Cancer: Different Impact on Disease Risk and Clinical Parameters in Smokers and Never-Smokers. Front Immunol. 2021;12:664474.CrossRefPubMedPubMedCentral
11.
go back to reference Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694–705.CrossRefPubMed Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694–705.CrossRefPubMed
13.
go back to reference Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Rodriguez IP, Chakravarthi BVSK, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.CrossRefPubMedPubMedCentral Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Rodriguez IP, Chakravarthi BVSK, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.CrossRefPubMedPubMedCentral
14.
go back to reference Halytskiy VA. MiRNA deregulation can contribute to breakdown of MHC I class antigen processing and presenting machinery in breast cancer cells. Eur J Cancer. 2019;110(1):S19.CrossRef Halytskiy VA. MiRNA deregulation can contribute to breakdown of MHC I class antigen processing and presenting machinery in breast cancer cells. Eur J Cancer. 2019;110(1):S19.CrossRef
15.
go back to reference D’Antona P, Cattoni M, Dominioni L, Poli A, Moretti F, Cinquetti R, et al. Serum miR-223: A Validated Biomarker for Detection of Early-Stage Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1926–33.CrossRefPubMed D’Antona P, Cattoni M, Dominioni L, Poli A, Moretti F, Cinquetti R, et al. Serum miR-223: A Validated Biomarker for Detection of Early-Stage Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1926–33.CrossRefPubMed
16.
go back to reference Pontén F, Jirström K, Uhlen M. The Human Protein Atlas–a tool for pathology. J Pathol. 2008;216(4):387–93.CrossRefPubMed Pontén F, Jirström K, Uhlen M. The Human Protein Atlas–a tool for pathology. J Pathol. 2008;216(4):387–93.CrossRefPubMed
17.
go back to reference Hanson AL, Cuddihy T, Haynes K, Loo D, Morton CJ, Oppermann U, et al. Genetic Variants in ERAP1 and ERAP2 Associated With Immune-Mediated Diseases Influence Protein Expression and the Isoform Profile. Arthritis Rheumatol. 2018;70(2):255–65.CrossRefPubMed Hanson AL, Cuddihy T, Haynes K, Loo D, Morton CJ, Oppermann U, et al. Genetic Variants in ERAP1 and ERAP2 Associated With Immune-Mediated Diseases Influence Protein Expression and the Isoform Profile. Arthritis Rheumatol. 2018;70(2):255–65.CrossRefPubMed
18.
go back to reference Paladini F, Fiorillo MT, Vitulano C, Tedeschi V, Piga M, Cauli A, et al. An allelic variant in the intergenic region between ERAP1 and ERAP2 correlates with an inverse expression of the two genes. Sci Rep. 2018;8(1):10398.CrossRefPubMedPubMedCentral Paladini F, Fiorillo MT, Vitulano C, Tedeschi V, Piga M, Cauli A, et al. An allelic variant in the intergenic region between ERAP1 and ERAP2 correlates with an inverse expression of the two genes. Sci Rep. 2018;8(1):10398.CrossRefPubMedPubMedCentral
19.
go back to reference Dimopoulou C, Lundgren JD, Sundal J, Ullum H, Aukrust P, Nielsen FC, et al. Variant in ERAP1 promoter region is associated with low expression in a patient with a Behçet-like MHC-I-opathy. J Hum Genet. 2020;65(3):325–35.CrossRefPubMed Dimopoulou C, Lundgren JD, Sundal J, Ullum H, Aukrust P, Nielsen FC, et al. Variant in ERAP1 promoter region is associated with low expression in a patient with a Behçet-like MHC-I-opathy. J Hum Genet. 2020;65(3):325–35.CrossRefPubMed
20.
go back to reference Yang S, Tang D, Zhao YC, Liu H, Luo S, Stinchcombe TE, et al. Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. Cancer Immunol Immunother. 2021;70(10):2819–33.CrossRefPubMedPubMedCentral Yang S, Tang D, Zhao YC, Liu H, Luo S, Stinchcombe TE, et al. Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. Cancer Immunol Immunother. 2021;70(10):2819–33.CrossRefPubMedPubMedCentral
21.
go back to reference Lonsdale J, Thomas J, Salvatore M, Philips R, Lo E, Shad S, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–5.CrossRef Lonsdale J, Thomas J, Salvatore M, Philips R, Lo E, Shad S, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–5.CrossRef
22.
go back to reference Yao Y, Wiśniewski A, Ma Q, Kowal A, Porębska I, Pawełczyk K, et al. Single Nucleotide Polymorphisms of the ERAP1 Gene and Risk of NSCLC: A Comparison of Genetically Distant Populations, Chinese and Caucasian. Arch Immunol Ther Exp (Warsz). 2016;64(Suppl 1):117–22.CrossRefPubMed Yao Y, Wiśniewski A, Ma Q, Kowal A, Porębska I, Pawełczyk K, et al. Single Nucleotide Polymorphisms of the ERAP1 Gene and Risk of NSCLC: A Comparison of Genetically Distant Populations, Chinese and Caucasian. Arch Immunol Ther Exp (Warsz). 2016;64(Suppl 1):117–22.CrossRefPubMed
23.
go back to reference Lysell J, Padyukov L, Kockum I, Nikamo P, Ståhle M. Genetic association with ERAP1 in psoriasis is confined to disease onset after puberty and not dependent on HLA-C*06. J Invest Dermatol. 2013;133(2):411–7.CrossRefPubMed Lysell J, Padyukov L, Kockum I, Nikamo P, Ståhle M. Genetic association with ERAP1 in psoriasis is confined to disease onset after puberty and not dependent on HLA-C*06. J Invest Dermatol. 2013;133(2):411–7.CrossRefPubMed
24.
go back to reference Stawczyk-Macieja M, Rębała K, Szczerkowska-Dobosz A, Wysocka J, Cybulska L, Kapińska E, et al. Evaluation of Psoriasis Genetic Risk Based on Five Susceptibility Markers in a Population from Northern Poland. PLoS One. 2016;11(9):e0163185.CrossRefPubMedPubMedCentral Stawczyk-Macieja M, Rębała K, Szczerkowska-Dobosz A, Wysocka J, Cybulska L, Kapińska E, et al. Evaluation of Psoriasis Genetic Risk Based on Five Susceptibility Markers in a Population from Northern Poland. PLoS One. 2016;11(9):e0163185.CrossRefPubMedPubMedCentral
25.
go back to reference Fu Y, Li X, Chen Y, Liu R, Wang R, Bai N. Association of ERAP1 gene polymorphisms with the susceptibility to psoriasis vulgaris: A case-control study. Medicine (Baltimore). 2018;97(41):e12828.CrossRefPubMed Fu Y, Li X, Chen Y, Liu R, Wang R, Bai N. Association of ERAP1 gene polymorphisms with the susceptibility to psoriasis vulgaris: A case-control study. Medicine (Baltimore). 2018;97(41):e12828.CrossRefPubMed
26.
go back to reference Küçükşahin O, Ateş A, Türkçapar N, Törüner M, Turgay M, Duman T, et al. Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey. Turk J Gastroenterol. 2016;27(4):317–24.CrossRefPubMed Küçükşahin O, Ateş A, Türkçapar N, Törüner M, Turgay M, Duman T, et al. Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey. Turk J Gastroenterol. 2016;27(4):317–24.CrossRefPubMed
27.
go back to reference Sasayama D, Hattori K, Ogawa S, Yokota Y, Matsumura R, Teraishi T, et al. Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome. Hum Mol Genet. 2017;26(1):44–51.PubMed Sasayama D, Hattori K, Ogawa S, Yokota Y, Matsumura R, Teraishi T, et al. Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome. Hum Mol Genet. 2017;26(1):44–51.PubMed
28.
go back to reference DeOcesano-Pereira C, Velloso FJ, Carreira ACO, Ribeiro CSP, Winnischofer SMB, Sogayar MC, et al. Post-Transcriptional Control of RNA Expression in Cancer. In: Fumiaki Uchiumi. Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects. 2018. p. 115–147. http://dx.doi.org/10.5772/intechopen.71861. DeOcesano-Pereira C, Velloso FJ, Carreira ACO, Ribeiro CSP, Winnischofer SMB, Sogayar MC, et al. Post-Transcriptional Control of RNA Expression in Cancer. In: Fumiaki Uchiumi. Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects. 2018. p. 115–147. http://​dx.​doi.​org/​10.​5772/​intechopen.​71861.
30.
go back to reference Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol. 2006;7(1):103–12.CrossRefPubMed Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N. The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol. 2006;7(1):103–12.CrossRefPubMed
Metadata
Title
Down-regulation of ERAP1 mRNA expression in non-small cell lung cancer
Authors
Marta Wagner
Maciej Sobczyński
Monika Jasek
Konrad Pawełczyk
Irena Porębska
Piotr Kuśnierczyk
Andrzej Wiśniewski
Publication date
01-12-2023
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10785-7

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine